Lipids in the nutritional support of the critically ill patients.
OBJECTIVE
This review reports recent findings on lipid use in artificial nutrition in patients with acute respiratory failure or severe sepsis or undergoing major surgery. It examines current knowledge of fatty acid safety, biologic effects, and the impact on patients' morbidity and mortality. The newly emerging area of genotypic influence and timing of immunonutrition is also discussed.


RESULTS
In acute respiratory distress syndrome, the debate concerning the use of long-chain fatty acids as opposed to physical mixtures of medium- and long-chain fatty acids, specifically regarding their effects on gas exchange and pulmonary hemodynamics, still remains unresolved. By contrast, providing fish oil fatty acids (mainly eicosapentaenoic and docosahexaenoic acids) and/or gamma-linolenic acid, seems to decrease harmful excessive inflammatory/immune activation and to improve clinical outcome. Similar effects, although not conclusively demonstrated, have been reported for n-3 fatty acid-enriched lipid emulsions in patients with sepsis. Few recent studies examined the impact of n-3 fatty acid-enriched enteral formulas on patients undergoing major surgery. Most studies focused on intravenous fish oil and suggest beneficial effects both on inflammatory/immune parameters and patient outcome. Studies suggest that lipid use in critically ill patients may be improved by increased knowledge of genetic determinants of severity of injury and response to therapeutic agents as well as by the development of tools that allow better timing of immunonutritional intervention.


CONCLUSIONS
Overall, lipids, in particular n-3 fatty acids, emerge as powerful nutrients with pharmacologic properties potentially improving prognosis in critically ill patients. However, heterogeneity in study design makes the interpretation of available studies difficult. Consequently, larger prospective, randomized, double-blind trials with comparable methodologies are necessary for detailed evaluation of the pharmacologic impact of lipids. In addition, a better knowledge of the influence of genotypic variation and postinjury inflammatory/immune temporal patterns may improve our current therapeutic use of various fatty acids.
Hasselmann
Michel
M
Service de Réanimation Médicale, Hôpitaux Universitaires de Strasbourg, Hôpital Civil, Strasbourg Cedex, France. michel.hasselmann@chru-strasbourg.fr
Reimund
Jean-Marie
JM
D002986:Clinical Trials as Topic; D003422:Critical Care; D016638:Critical Illness; D004750:Enteral Nutrition; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005526:Food, Formulated; D006801:Humans; D009752:Nutritional Status; D019990:Perioperative Care; D011183:Postoperative Complications
D015525:Fatty Acids, Omega-3